EP Patent

EP3342401A1 — Bilayer tablet formulations of dabigatran etexilate

Assigned to Sanovel Ilac Sanayi ve Ticaret AS · Expires 2018-07-04 · 8y expired

What this patent protects

The present invention relates to a pharmaceutical bilayer tablet comprising dabigatran etexilate free base or pharmaceutically acceptable salts of dabigatran etexilate and at least one pharmaceutically acceptable excipient.

USPTO Abstract

The present invention relates to a pharmaceutical bilayer tablet comprising dabigatran etexilate free base or pharmaceutically acceptable salts of dabigatran etexilate and at least one pharmaceutically acceptable excipient.

Drugs covered by this patent

Patent Metadata

Patent number
EP3342401A1
Jurisdiction
EP
Classification
—
Expires
2018-07-04
Drug substance claim
No
Drug product claim
No
Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.